Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) saw unusually-high trading volume on Wednesday . Approximately 1,703,538 shares changed hands during trading, an increase of 46% from the previous session’s volume of 1,165,130 shares.The stock last traded at $8.92 and had previously closed at $9.22.

ACHN has been the subject of several analyst reports. Zacks Investment Research upgraded Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Tuesday, April 26th. Leerink Swann reiterated a “market perform” rating and set a $9.00 price objective (up previously from $7.00) on shares of Achillion Pharmaceuticals in a report on Wednesday, May 4th. Robert W. Baird reiterated an “outperform” rating and set a $10.00 price objective on shares of Achillion Pharmaceuticals in a report on Monday, June 6th. Chardan Capital initiated coverage on Achillion Pharmaceuticals in a report on Thursday, July 14th. They set a “sell” rating and a $4.00 price objective for the company. Finally, Jefferies Group reiterated a “hold” rating on shares of Achillion Pharmaceuticals in a report on Thursday, May 5th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $9.63.

The firm has a 50 day moving average of $8.75 and a 200 day moving average of $8.20. The company has a market cap of $1.18 billion and a P/E ratio of 175.51.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. During the same quarter last year, the company posted ($0.25) earnings per share. On average, analysts anticipate that Achillion Pharmaceuticals Inc. will post ($0.63) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Achillion Pharmaceuticals stock. Rhumbline Advisers raised its stake in Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) by 14.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 117,525 shares of the biopharmaceutical company’s stock after buying an additional 14,425 shares during the period. Rhumbline Advisers owned about 0.09% of Achillion Pharmaceuticals worth $1,268,000 at the end of the most recent reporting period.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.